Health policy or intellectual property policy? The fight over Bill C-91
Adapted from the Canadian Healthcare Association's submission to the House of Commons Standing Committee on Industry currently reviewing Bill C-91, an Act to amend the Patent Act. Discusses the controversy surrounding this legislation, which extended patent protection to brand-name drug manufacturers to 20 years before generic copies of pharmaceuticals can be introduced on to the market.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.